MeSH D003699 - hepatitis d
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus | 2004-06-04 | |||
| Interferon alfa-2a | Roferon-A | 1986-06-04 | ||||
| Merck & Co | Interferon alfa-2b | Intron A | 1986-06-04 | |||
| Interferon alfa-2b | IntronA | 2000-03-09 | ||||
| Peginterferon alfa-2b | PegIntron | 2001-01-19 | ||||
| Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack | 2008-06-13 | ||||
| Interferon alfa-2b | Viraferon | 2000-03-09 | ||||
| Peginterferon alfa-2b | ViraferonPeg | 2000-05-28 | ||||
| Horizon Therapeutics Public | Interferon gamma-1b | Actimmune | 1999-02-25 | $122.816 M | Q3/22-Q2/23 | |
| Pharma& | Peginterferon alfa-2a | Pegasys | 2002-10-16 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/7
Phase 3
100%4/4
Approved: 4Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use